Data presented by ViiV Healthcare and Gilead Sciences at the 11th International AIDS Society Conference on HIV Science (IAS 2021):
ViiV Healthcare:
The 48-week data from the phase III SALSA study represent a diverse patient population, and demonstrate comparable safety for 2-drug regimen Dovato versus continuation of a current antiretroviral regimen of at least 3 drugs, reinforcing its use in a switch setting
Healthcare teams from a wide variety of US HIV clinics reported that optimal implementation of long-acting cabotegravir and rilpivirine dosed monthly was achieved within 1 – 3 months, and implementation was acceptable, appropriate and feasible; Majority of patients (74%) in the study reported few barriers to monthly injection appointments even during COVID-19
Gilead Sciences:
99% of participants achieved and maintained an undetectable viral load with Biktarvy in pooled analysis of 192-week data from open-label extension period of two Phase 3 trials in treatment-naïve adults
72-week data from the BRAAVE study demonstrate 99% of black adults who are virologically suppressed and switched to Biktarvy from a standard regimen achieved and maintained an undetectable viral load
Week 26 data from the CAPELLA trial show lenacapavir leads to high rates of virologic suppression in heavily treatment-experienced people living with multi-drug resistant HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.